Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jian Zheng, Xiaoru Bai, Chengyu Hong, Hong Gao & Xiaoling Li. (2016) Meta-analysis of the incidence and risk of arterial and venous thromboembolic events associated with anti-EGFR agents in non-small-cell lung cancer patients. Expert Review of Clinical Pharmacology 9:10, pages 1389-1395.
Read now
Read now
Omar Abdel-Rahman, Hoda Ahmed & Hesham ElHalawani. (2016) Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis. Expert Review of Respiratory Medicine 10:2, pages 223-234.
Read now
Read now
Omar Abdel-Rahman, Hesham ElHalawani & Shaimaa Essam-Eldin. (2016) S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines. Expert Opinion on Drug Safety 15:1, pages 5-20.
Read now
Read now
Omar Abdel-Rahman, Hesham ElHalawani, Hoda Ahmed & Mahmoud Ellithy. (2015) Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. Expert Review of Gastroenterology & Hepatology 9:11, pages 1433-1445.
Read now
Read now
Omar Abdel-Rahman & Hesham ElHalawani. (2015) Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis. Expert Opinion on Drug Safety 14:10, pages 1495-1506.
Read now
Read now
Articles from other publishers (7)
Daniel F. Carr, Seyoum Ayehunie, Andrea Davies, Carrie A. Duckworth, Stephanie French, Neil Hall, Syed Hussain, Howard R. Mellor, Alan Norris, B. Kevin Park, Alexander Penrose, D. Mark Pritchard, Chris S. Probert, Shashi Ramaiah, Claire Sadler, Michael Schmitt, Alison Shaw, James E. Sidaway, Robert G. Vries, Matthew Wagoner & Munir Pirmohamed. (2017) Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. Pharmacology & Therapeutics 172, pages 181-194.
Crossref
Crossref
M. Sassier, L. Peyro-Saint-Paul, B. Clarisse, A. Leconte, A. Coquerel, J. Alexandre, S. Fedrizzi, E. Leroy-Terquem, A. Madroszyk & R. Gervais. (2016) Chemotherapy (platinum and pemetrexed) in combination with erlotinib in non-small cell lung cancer induces major gastrointestinal toxicity: two case reports from the FLARE/GFPC 03-2013 study. Journal of Clinical Pharmacy and Therapeutics 41:4, pages 447-448.
Crossref
Crossref
Omar Abdel-Rahman & Mona Fouad. (2016) Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting. Future Oncology 12:6, pages 871-879.
Crossref
Crossref
Omar Abdel-Rahman & Hesham ElHalawani. (2016) S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis. Future Oncology 12:5, pages 701-713.
Crossref
Crossref
David Reeves. 2016. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
479
491
.
Omar Abdel-Rahman, Hesham ElHalawani & Mona Fouad. (2015) Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy 7:11, pages 1213-1227.
Crossref
Crossref
Omar Abdel-Rahman & Hesham Elhalawani. (2015) Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. Future Oncology 11:7, pages 1109-1122.
Crossref
Crossref